Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else?

The proline-specific dipeptidyl aminopeptidase IV (DPP IV, DPP-4, CD26), widely expressed in mammalians, releases X-Pro/Ala dipeptides from the N-terminus of peptides. DPP IV is responsible of the degradation of the incretin peptide hormones regulating blood glucose levels. Several families of DPP IV inhibitors have been synthesized and evaluated. Their positive effects on the degradation of the incretins and the control of blood glucose levels have been demonstrated in biological models and in clinical trials. Presently, several DPP IV inhibitors, the "gliptins", are approved for type 2 diabetes or are under clinical evaluation. However, the gliptins may also be of therapeutic interest for other diseases beyond the inhibition of incretin degradation. In this Perspective, the biological functions and potential substrates of DPP IV enzymes are reviewed and the characteristics of the DPP IV inhibitors are discussed in view of type 2 diabetes and further therapeutic interest.

[1]  F. Naider,et al.  Proline-dependent structural and biological properties of peptides and proteins. , 1993, Critical reviews in biochemistry and molecular biology.

[2]  Y. Asada,et al.  Expression of dipeptidyl aminopeptidase IV activity in human lung carcinoma , 1993, Histopathology.

[3]  B. Fleischer,et al.  CD26: a surface protease involved in T-cell activation. , 1994, Immunology today.

[4]  B. O'connor,et al.  Proline specific peptidases. , 1997, Biochimica et biophysica acta.

[5]  V. Reuter,et al.  Expression and localization of aminopeptidase A, aminopeptidase N, and dipeptidyl peptidase IV in benign and malignant human prostate tissue , 1997, The Prostate.

[6]  László Polgár,et al.  Prolyl Oligopeptidase An Unusual β-Propeller Domain Regulates Proteolysis , 1998, Cell.

[7]  J. Holst,et al.  Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. , 1998, Diabetes.

[8]  A. Houghton,et al.  A Role for Dipeptidyl Peptidase IV in Suppressing the Malignant Phenotype of Melanocytic Cells , 1999, The Journal of experimental medicine.

[9]  Rolf Mentlein,et al.  Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides , 1999, Regulatory Peptides.

[10]  A. Lambeir,et al.  Structure-activity relationship of diaryl phosphonate esters as potent irreversible dipeptidyl peptidase IV inhibitors. , 1999, Journal of medicinal chemistry.

[11]  R. Martin,et al.  Dipeptidyl peptidase IV in inflammatory CNS disease. , 2000, Advances in experimental medicine and biology.

[12]  W. Brandt,et al.  Down-regulation of T Cell Activation following Inhibition of Dipeptidyl Peptidase IV/CD26 by the N-terminal Part of the Thromboxane A2 Receptor* , 2000, The Journal of Biological Chemistry.

[13]  B. Hemmer,et al.  Dipeptidyl peptidase IV (CD26): role in T cell activation and autoimmune disease. , 2000, Advances in experimental medicine and biology.

[14]  B. Klapp,et al.  Dipeptidyl peptidase IV (DP IV, CD26) in patients with inflammatory bowel disease. , 2001, Scandinavian journal of gastroenterology.

[15]  L. Juillerat-Jeanneret,et al.  Regulation of peptidase activity in a three-dimensional aggregate model of brain tumor vasculature , 2002, Cell and Tissue Research.

[16]  J. Ulrichová,et al.  Quaternary benzo[c]phenanthridine alkaloids as inhibitors of aminopeptidase N and dipeptidyl peptidase IV , 2002, Phytotherapy research : PTR.

[17]  T. Hughes,et al.  1-[2-[(5-Cyanopyridin-2-yl)amino]ethylamino]acetyl-2-(S)-pyrrolidinecarbonitrile: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. , 2002, Journal of medicinal chemistry.

[18]  L. Polgár.  The prolyl oligopeptidase family , 2002, Cellular and Molecular Life Sciences CMLS.

[19]  C. Craik,et al.  Catalytic properties and inhibition of proline-specific dipeptidyl peptidases II, IV and VII. , 2003, The Biochemical journal.

[20]  Walter Huber,et al.  Structural basis of proline-specific exopeptidase activity as observed in human dipeptidyl peptidase-IV. , 2003, Structure.

[21]  H. Kajiyama,et al.  Dipeptidyl peptidase IV overexpression induces up-regulation of E-cadherin and tissue inhibitors of matrix metalloproteinases, resulting in decreased invasive potential in ovarian carcinoma cells. , 2003, Cancer research.

[22]  Robert Huber,et al.  The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[23]  J. Kozarich,et al.  Prolyl peptidases: a serine protease subfamily with high potential for drug discovery. , 2003, Current opinion in chemical biology.

[24]  Sven Branner,et al.  Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog , 2003, Nature Structural Biology.

[25]  Dongsung Lim,et al.  Inhibition of dipeptidyl peptidase IV (DPP IV) by 2-(2-amino-1-fluoro-propylidene)-cyclopentanecarbonitrile, a fluoroolefin containing peptidomimetic. , 2003, Bioorganic & medicinal chemistry.

[26]  T. Hughes,et al.  1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. , 2003, Journal of medicinal chemistry.

[27]  H. Kajiyama,et al.  Expression of CD26/dipeptidyl peptidase IV in endometrial adenocarcinoma and its negative correlation with tumor grade. , 2003, Advances in experimental medicine and biology.

[28]  T. Kelly,et al.  DPPIV, seprase, and related serine peptidases in multiple cellular functions. , 2003, Current topics in developmental biology.

[29]  R. Parker,et al.  Synthesis of novel potent dipeptidyl peptidase IV inhibitors with enhanced chemical stability: interplay between the N-terminal amino acid alkyl side chain and the cyclopropyl group of alpha-aminoacyl-l-cis-4,5-methanoprolinenitrile-based inhibitors. , 2004, Journal of medicinal chemistry.

[30]  C. Pethiyagoda,et al.  Dipeptidyl peptidase IV (DPPIV) inhibits cellular invasion of melanoma cells , 2004, Clinical & Experimental Metastasis.

[31]  J. Holst,et al.  Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus. , 2004, Current opinion in pharmacology.

[32]  Takeshi Watanabe,et al.  PT-100, a Small Molecule Dipeptidyl Peptidase Inhibitor, Has Potent Antitumor Effects and Augments Antibody-Mediated Cytotoxicity via a Novel Immune Mechanism , 2004, Cancer Research.

[33]  Petr Busek,et al.  Dipeptidyl peptidase IV activity and/or structure homologues (DASH) and their substrates in cancer. , 2004, The international journal of biochemistry & cell biology.

[34]  V. Kalish,et al.  Ketopyrrolidines and ketoazetidines as potent dipeptidyl peptidase IV (DPP IV) inhibitors. , 2004, Bioorganic & medicinal chemistry letters.

[35]  N. Thornberry,et al.  Potent and selective proline derived dipeptidyl peptidase IV inhibitors. , 2004, Bioorganic & medicinal chemistry letters.

[36]  A. Houghton,et al.  Role for dipeptidyl peptidase IV in tumor suppression of human non small cell lung carcinoma cells , 2004, International journal of cancer.

[37]  Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. , 2004, Journal of medicinal chemistry.

[38]  H. Fukushima,et al.  Synthesis and structure-activity relationships of potent 3- or 4-substituted-2-cyanopyrrolidine dipeptidyl peptidase IV inhibitors. , 2004, Bioorganic & medicinal chemistry.

[39]  Silja Weber,et al.  Aminomethylpyrimidines as novel DPP-IV inhibitors: a 10(5)-fold activity increase by optimization of aromatic substituents. , 2004, Bioorganic & medicinal chemistry letters.

[40]  Y. Umezawa,et al.  Synthesis and biological activity of sulphostin analogues, novel dipeptidyl peptidase IV inhibitors. , 2005, Bioorganic & medicinal chemistry.

[41]  You-Jung Park,et al.  Discovery of potent and selective phenylalanine based dipeptidyl peptidase IV inhibitors. , 2004, Bioorganic & medicinal chemistry letters.

[42]  M. Gorrell.  Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. , 2005, Clinical science.

[43]  G. Scapin,et al.  (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. , 2005, Journal of medicinal chemistry.

[44]  R. Parker,et al.  Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. , 2005, Journal of medicinal chemistry.

[45]  J. Holst,et al.  Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig , 2005, Diabetologia.

[46]  H. Hsiung,et al.  Potent peptide agonists for human melanocortin 3 and 4 receptors derived from enzymatic cleavages of human β-MSH(5–22) by dipeptidyl peptidase I and dipeptidyl peptidase IV , 2005, Peptides.

[47]  J. Foley,et al.  Improved glycaemic control with dipeptidyl peptidase‐4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response , 2005, Diabetes, obesity & metabolism.

[48]  Diprolyl nitriles as potent dipeptidyl peptidase IV inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[49]  L. Juillerat-Jeanneret,et al.  Determination of intracellular prolyl/glycyl proteases in intact living human cells and protoporphyrin IX production as a reporter system. , 2005, Chemistry & biology.

[50]  H. Sakashita,et al.  1-((S)-gamma-substituted prolyl)-(S)-2-cyanopyrrolidine as a novel series of highly potent DPP-IV inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[51]  R. Mentlein.  Therapeutic assessment of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase IV inhibitors as potential antidiabetic drugs , 2005, Expert opinion on investigational drugs.

[52]  T. Tomaszek,et al.  2-Cyano-4-fluoro-1-thiovalylpyrrolidine analogues as potent inhibitors of DPP-IV. , 2005, Bioorganic & medicinal chemistry letters.

[53]  C. Herling,et al.  Immunopathology and Infectious Disease Circulating CD26 Is Negatively Associated with Inflammation in Human and Experimental Arthritis , 2022 .

[54]  H. Kajiyama,et al.  Dipeptidyl peptidase IV in tumor progression. , 2005, Biochimica et biophysica acta.

[55]  G. Scapin,et al.  Discovery of potent, selective, and orally bioavailable oxadiazole-based dipeptidyl peptidase IV inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[56]  T. Saeki,et al.  E3024, 3-but-2-ynyl-5-methyl-2-piperazin-1-yl-3,5-dihydro-4H-imidazo[4,5-d]pyridazin-4-one tosylate, is a novel, selective and competitive dipeptidyl peptidase-IV inhibitor. , 2006, European journal of pharmacology.

[57]  H. Sakashita,et al.  [(S)-gamma-(Arylamino)prolyl]thiazolidine compounds as a novel series of potent and stable DPP-IV inhibitors. , 2006, Bioorganic & medicinal chemistry.

[58]  J. Peters.  11 Years of cyanopyrrolidines as DPP-IV inhibitors. , 2007, Current topics in medicinal chemistry.

[59]  M. Ammirati,et al.  Design and synthesis of potent amido- and benzyl-substituted cis-3-amino-4-(2-cyanopyrrolidide)pyrrolidinyl DPP-IV inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[60]  G. Scapin,et al.  Design, synthesis, and biological evaluation of triazolopiperazine-based beta-amino amides as potent, orally active dipeptidyl peptidase IV (DPP-4) inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[61]  G. Scapin,et al.  Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin. , 2007, Bioorganic & medicinal chemistry letters.

[62]  S. Ono,et al.  Lead optimization of [( S )-γ-(arylamino)prolyl]thiazolidine focused on γ-substituent: Indoline compounds as potent DPP-IV inhibitors , 2007 .

[63]  Jie-Oh Lee,et al.  Synthesis, biological evaluation and structural determination of beta-aminoacyl-containing cyclic hydrazine derivatives as dipeptidyl peptidase IV (DPP-IV) inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[64]  P. Van der Veken,et al.  Prolyl peptidases related to dipeptidyl peptidase IV: potential of specific inhibitors in drug discovery. , 2007, Current topics in medicinal chemistry.

[65]  H. Hsieh,et al.  3-[2-((2S)-2-cyano-pyrrolidin-1-yl)-2-oxo-ethylamino]-3-methyl-butyramide analogues as selective DPP-IV inhibitors for the treatment of type-II diabetes. , 2007, Bioorganic & medicinal chemistry letters.

[66]  D. Kassel,et al.  Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. , 2007, Journal of medicinal chemistry.

[67]  [(S)-gamma-(4-Aryl-1-piperazinyl)-l-prolyl]thiazolidines as a novel series of highly potent and long-lasting DPP-IV inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[68]  R. Sheridan,et al.  Modeling assisted rational design of novel, potent, and selective pyrrolopyrimidine DPP-4 inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[69]  H. Nar,et al.  8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. , 2007, Journal of medicinal chemistry.

[70]  Bernd Kuhn,et al.  Molecular recognition of ligands in dipeptidyl peptidase IV. , 2007, Current topics in medicinal chemistry.

[71]  N. Thornberry,et al.  Discovery of JANUVIA TM (Sitagliptin), a Selective Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type2 Diabetes. , 2007 .

[72]  Jr . John R. White.  Dipeptidyl Peptidase-IV Inhibitors: Pharmacological Profile and Clinical Use , 2008 .

[73]  Jie-Oh Lee,et al.  Synthesis and biological evaluation of homopiperazine derivatives with beta-aminoacyl group as dipeptidyl peptidase IV inhibitors. , 2008, Bioorganic & medicinal chemistry letters.

[74]  M. Toda,et al.  Design and synthesis of DPP-IV inhibitors lacking the electrophilic nitrile group. , 2008, Bioorganic & medicinal chemistry.

[75]  Prolyl-Specific Peptidases and Their Inhibitors in Biological Processes , 2008 .

[76]  L. Juillerat-Jeanneret,et al.  The prolyl-aminodipeptidases and their inhibitors as therapeutic targets for fibrogenic disorders. , 2009, Mini reviews in medicinal chemistry.

[77]  Joo-Youn Cho,et al.  Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers. , 2009, British journal of clinical pharmacology.

[78]  L. Juillerat-Jeanneret,et al.  Peptides from Lactobacillus hydrolysates of bovine milk caseins inhibit prolyl-peptidases of human colon cells. , 2011, Journal of agricultural and food chemistry.

[79]  M. Oka,et al.  Synthesis and pharmacological characterization of potent, selective, and orally bioavailable isoindoline class dipeptidyl peptidase IV inhibitors , 2011, Organic and medicinal chemistry letters.

[80]  P. Lu,et al.  Discovery of potent dipeptidyl peptidase IV inhibitors derived from β-aminoamides bearing substituted [1,2,3]-triazolopiperidines for the treatment of type 2 diabetes. , 2011, Bioorganic & medicinal chemistry letters.

[81]  F. Facchiano,et al.  High mobility group box 1 is a novel substrate of dipeptidyl peptidase-IV , 2011, Diabetologia.

[82]  S. Kalra,et al.  Choosing a Gliptin , 2011, Indian journal of endocrinology and metabolism.

[83]  J. Yano,et al.  Discovery of a 3-pyridylacetic acid derivative (TAK-100) as a potent, selective and orally active dipeptidyl peptidase IV (DPP-4) inhibitor. , 2011, Journal of medicinal chemistry.

[84]  Dipeptidyl peptidase-4 inhibition: linking chemical properties to clinical safety. , 2011, Current medicinal chemistry.

[85]  Y. Hu,et al.  Recent advances in non-peptidomimetic dipeptidyl peptidase 4 inhibitors: medicinal chemistry and preclinical aspects. , 2012, Current medicinal chemistry.

[86]  Drug repositioning for Alzheimer's disease , 2012, Nature Reviews Drug Discovery.

[87]  E. Deeks.  Linagliptin: a review of its use in the management of type 2 diabetes mellitus. , 2012, Drugs.

[88]  E. Jackson,et al.  Dipeptidyl Peptidase IV Regulates Proliferation of Preglomerular Vascular Smooth Muscle and Mesangial Cells , 2012, Hypertension.

[89]  P. Brubaker,et al.  Novel biological action of the dipeptidylpeptidase-IV inhibitor, sitagliptin, as a glucagon-like peptide-1 secretagogue. , 2012, Endocrinology.

[90]  Chia-Ling Jao,et al.  Dipeptidyl-peptidase IV inhibitory activity of peptides derived from tuna cooking juice hydrolysates , 2012, Peptides.

[91]  S. Gandhi,et al.  A novel long acting DPP-IV inhibitor PKF-275-055 stimulates β-cell proliferation resulting in improved glucose homeostasis in diabetic rats. , 2012, Biochemical pharmacology.

[92]  A. Scheen.  A review of gliptins in 2011 , 2012, Expert opinion on pharmacotherapy.

[93]  Mi-kyung Kim,et al.  DA-1229, a novel and potent DPP4 inhibitor, improves insulin resistance and delays the onset of diabetes. , 2012, Life sciences.

[94]  Linagliptin: a novel methylxanthin based approved dipeptidyl peptidase-4 inhibitor. , 2012, Current drug targets.

[95]  I. De Meester,et al.  Dipeptidyl peptidase 4 as a therapeutic target in ischemia/reperfusion injury. , 2012, Pharmacology & therapeutics.

[96]  J. Huh,et al.  Sitagliptin increases tau phosphorylation in the hippocampus of rats with type 2 diabetes and in primary neuron cultures , 2012, Neurobiology of Disease.

[97]  Mukul R Jain,et al.  Long-acting peptidomimetics based DPP-IV inhibitors. , 2012, Bioorganic & medicinal chemistry letters.

[98]  Y. Izumiya,et al.  A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. , 2012, Journal of the American College of Cardiology.

[99]  W. Jusko,et al.  Mechanism-based population pharmacokinetic modelling in diabetes: vildagliptin as a tight binding inhibitor and substrate of dipeptidyl peptidase IV. , 2012, British journal of clinical pharmacology.

[100]  M. Son,et al.  Dipeptidyl peptidase-4 inhibitor with β-amino amide scaffold: synthesis, SAR and biological evaluation. , 2012, Bioorganic & medicinal chemistry letters.

[101]  D. Matthews,et al.  Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis , 2012, BMJ : British Medical Journal.

[102]  E. Li-Chan,et al.  Peptides derived from atlantic salmon skin gelatin as dipeptidyl-peptidase IV inhibitors. , 2012, Journal of agricultural and food chemistry.

[103]  M. Santana,et al.  Dipeptidyl-peptidase-IV by cleaving neuropeptide Y induces lipid accumulation and PPAR-γ expression , 2012, Peptides.

[104]  S. K. Park,et al.  Dipeptidyl Peptidase IV Inhibitor Attenuates Kidney Injury in Streptozotocin-Induced Diabetic Rats , 2012, Journal of Pharmacology and Experimental Therapeutics.

[105]  G. Derosa,et al.  Dipeptidyl peptidase-4 inhibitors: 3 years of experience. , 2012, Diabetes technology & therapeutics.

[106]  Hongjian Xu,et al.  Novel pyrrolopyrimidine analogues as potent dipeptidyl peptidase IV inhibitors based on pharmacokinetic property-driven optimization. , 2012, European journal of medicinal chemistry.

[107]  I. De Meester,et al.  CD26/DPP-4 inhibition recruits regenerative stem cells via stromal cell-derived factor-1 and beneficially influences ischaemia-reperfusion injury in mouse lung transplantation. , 2012, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[108]  Guixia Liu,et al.  Identification of diverse dipeptidyl peptidase IV inhibitors via structure-based virtual screening , 2012, Journal of Molecular Modeling.

[109]  F. Watt,et al.  Upregulation of CD26 expression in epithelial cells and stromal cells during wound-induced skin tumour formation , 2012, Oncogene.

[110]  Hualiang Jiang,et al.  Synthesis, Structure–Activity Relationship, and Pharmacophore Modeling Studies of Pyrazole‐3‐Carbohydrazone Derivatives as Dipeptidyl Peptidase IV Inhibitors , 2012, Chemical biology & drug design.

[111]  S. Gough,et al.  Recent advances in incretin‐based therapies , 2012, Clinical endocrinology.

[112]  D. E. Clark,et al.  Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes. , 2012, Bioorganic & medicinal chemistry letters.

[113]  Hong Liu,et al.  Design, Synthesis, Structure–Activity Relationships, and Docking Studies of 1‐(γ‐1,2,3‐Triazol Substituted Prolyl)‐(S)‐3,3‐Difluoropyrrolidines as a Novel Series of Potent and Selective Dipeptidyl Peptidase‐4 Inhibitors , 2013, Chemical biology & drug design.

[114]  J. A. Kim,et al.  A multicentre, multinational, randomized, placebo‐controlled, double‐blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15‐0444) in patients with type 2 diabetes , 2013, Diabetes, obesity & metabolism.

[115]  Ryuzo Kawamori,et al.  Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice. , 2013, Endocrinology.

[116]  P. Cowley,et al.  Recent disclosures of clinical candidates (SMR Award Lecture) - Highlights from the Society for Medicines Research Symposium, held on December 5th 2012 at the National Heart & Lung Institute (NHLI), London, UK , 2013, Drugs of the Future.

[117]  S. Davis,et al.  A review of the efficacy and safety of oral antidiabetic drugs , 2013, Expert opinion on drug safety.

[118]  Synthesis and biological evaluation of xanthine derivatives on dipeptidyl peptidase 4. , 2013, Chemical & pharmaceutical bulletin.

[119]  B. Monz,et al.  A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications: an example using DPP-4 inhibitors, sitagliptin and linagliptin, in treatment of type 2 diabetes mellitus , 2013, BMJ Open.

[120]  C. Gleissner,et al.  Effects of vildagliptin (Galvus®) therapy in patients with type 2 diabetes mellitus after heart transplantation , 2013, Drug design, development and therapy.